These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 26094958

  • 1. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
    Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.
    Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [Abstract] [Full Text] [Related]

  • 3. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 4. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.
    Neumann T, Hofbauer LC, Rauner M, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Hamann C, Sämann A.
    Clin Endocrinol (Oxf); 2014 May; 80(5):649-55. PubMed ID: 24237244
    [Abstract] [Full Text] [Related]

  • 5. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
    Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE.
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M.
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.
    Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE.
    J Clin Endocrinol Metab; 2010 May; 95(5):2248-53. PubMed ID: 20305005
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling.
    Wu Y, Xu SY, Liu SY, Xu L, Deng SY, He YB, Xian SC, Liu YH, Ni GX.
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):470-478. PubMed ID: 28239825
    [Abstract] [Full Text] [Related]

  • 19. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
    Wang N, Xue P, Wu X, Ma J, Wang Y, Li Y.
    Endocr Res; 2018 Feb; 43(1):29-38. PubMed ID: 28972408
    [Abstract] [Full Text] [Related]

  • 20. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.